Latest news
Update on trials for future treatment of biliary atresia
As many of the young people and families we support are affected by biliary atresia, we’d like to update you on two pieces of research in this area:
Ipsen evaluation of Bylvay
Ipsen have announced the results of their Phase ...
The EMERALD study
Trial status: active not recruiting
Trial ID: NCT06823713
What is the EMERALD study?
EMERALD is a clinical trial designed to test if a new treatment called RTX001 is safe, easy to cope with, and works well for people suffering ...
New Lancet Commission Highlights the Vital Role of Primary Care in Tackling Liver Disease
A major new Lancet Gastroenterology & Hepatology Commission, published today, has shone a spotlight on the crucial role that primary care can play in preventing, detecting and managing liver disease. We were proud to contribute to ...
The MATCH trial – testing Macrophage cells to treat liver cirrhosis
This page is a summary of the MATCH trial. The trial looked at the possibility of using a type of white blood cell called a macrophage to treat liver cirrhosis.
What are macrophages?
We have lots of different types of white blood ...
The OPAL study
Trial status: Active, not recruiting
Trial ID: NCT06380335
What is OPAL?
OPAL is an observational study sponsored by Resolution Therapeutics. 11 hospitals across England and Scotland are participating in the study.
OPAL ...
A clinical study for people living with alcohol-related liver disease (ARLD)
The STARLIGHT Study is testing a study drug to see if it can reduce the harmful effects of alcohol on the liver in adults with ARLD who:
• Are 18 to 70 years of age.
• Have drunk alcohol within the last 4 months.
• Have been ...
New research highlights stark inequalities in access to life-saving liver transplants
New research published today reveals a stark reality for people with chronic liver disease in England: despite facing a high risk of death after emergency hospital admission, the vast majority are not receiving a potentially ...
New study aims to improve liver health after menopause
Researchers from Imperial College London will look at a treatment called kisspeptin. They hope to find out if it has health benefits for post menopause women with signs of MASLD.
After menopause, hormone changes can raise the risk ...
Recreating metabolic liver disease in the lab: how the MIMIC project could change MASLD research
One of the most common causes of chronic liver disease in the UK is MASLD. This stands for metabolic dysfunction‑associated steatotic liver disease. It was previously known as non-alcoholic fatty liver disease or NAFLD.
MASLD is ...
British Liver Trust delighted to be supporting major new groundbreaking liver study
The largest liver study in the history of the NHS is due for roll out next year, with the aim of preventing thousands of people at risk of liver disease from needing hospital care.
The study is funded by the National Institute for ...
Unlocking the health benefits of precision dietary care for fatty liver disease
Researchers at the Royal Free London are leading a consortium which has received a £1.4 million grant to discover a way to deliver personalised dietary care for patients with obesity and at risk of developing liver disease.
The team ...
Do you have Wilson’s Disease? You could help with a new clinical trial.
Please note: this trial is no longer recruiting participants.
Wilson’s disease is a rare, inherited liver condition. People with Wilson’s disease have to take medicine for their whole life to stop copper building up in their ...
No results found.
More from Liver UK
Check your risk
Find out if you’re at risk of liver disease using our simple at-risk checker for adults.
Find out more
Support us
Make a donation to help ensure everyone affected by liver disease gets the information and support they need.
Find out more
Keep up to date
Keep up to date with the charity’s news by registering for our email newsletter & updates.
Find out more
No results found.